95 related articles for article (PubMed ID: 10359211)
1. An effective strategy of human tumor vaccine modification by coupling bispecific costimulatory molecules.
Haas C; Herold-Mende C; Gerhards R; Schirrmacher V
Cancer Gene Ther; 1999; 6(3):254-62. PubMed ID: 10359211
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
[TBL] [Abstract][Full Text] [Related]
3. T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Vaccine; 2005 Mar; 23(19):2439-53. PubMed ID: 15752830
[TBL] [Abstract][Full Text] [Related]
4. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins.
Aigner M; Janke M; Lulei M; Beckhove P; Fournier P; Schirrmacher V
Int J Oncol; 2008 Apr; 32(4):777-89. PubMed ID: 18360705
[TBL] [Abstract][Full Text] [Related]
5. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus.
Schirrmacher V; Haas C; Bonifer R; Ahlert T; Gerhards R; Ertel C
Gene Ther; 1999 Jan; 6(1):63-73. PubMed ID: 10341877
[TBL] [Abstract][Full Text] [Related]
6. Immunization with virus-modified tumor cells.
Schirrmacher V; Ahlert T; Pröbstle T; Steiner HH; Herold-Mende C; Gerhards R; Hagmüller E; Steiner HH
Semin Oncol; 1998 Dec; 25(6):677-96. PubMed ID: 9865682
[TBL] [Abstract][Full Text] [Related]
7. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection.
Schirrmacher V; Haas C; Bonifer R; Ertel C
Clin Cancer Res; 1997 Jul; 3(7):1135-48. PubMed ID: 9815793
[TBL] [Abstract][Full Text] [Related]
8. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
9. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
Strauss G; Gückel B; Wallwiener D; Moldenhauer G
Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
[TBL] [Abstract][Full Text] [Related]
10. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
11. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2.
Janke M; Peeters B; Zhao H; de Leeuw O; Moorman R; Arnold A; Ziouta Y; Fournier P; Schirrmacher V
Int J Oncol; 2008 Oct; 33(4):823-32. PubMed ID: 18813797
[TBL] [Abstract][Full Text] [Related]
12. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells.
Termeer CC; Schirrmacher V; Bröcker EB; Becker JC
Cancer Gene Ther; 2000 Feb; 7(2):316-23. PubMed ID: 10770642
[TBL] [Abstract][Full Text] [Related]
13. A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.
Haas C; Lulei M; Fournier P; Arnold A; Schirrmacher V
Int J Cancer; 2006 Feb; 118(3):658-67. PubMed ID: 16108015
[TBL] [Abstract][Full Text] [Related]
14. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing.
Grosse-Hovest L; Hartlapp I; Marwan W; Brem G; Rammensee HG; Jung G
Eur J Immunol; 2003 May; 33(5):1334-40. PubMed ID: 12731059
[TBL] [Abstract][Full Text] [Related]
15. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
[TBL] [Abstract][Full Text] [Related]
16. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
[TBL] [Abstract][Full Text] [Related]
17. Expression of a variant of CD28 on a subpopulation of human NK cells: implications for B7-mediated stimulation of NK cells.
Galea-Lauri J; Darling D; Gan SU; Krivochtchapov L; Kuiper M; Gäken J; Souberbielle B; Farzaneh F
J Immunol; 1999 Jul; 163(1):62-70. PubMed ID: 10384100
[TBL] [Abstract][Full Text] [Related]
18. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
Woo EY; Chu CS; Goletz TJ; Schlienger K; Yeh H; Coukos G; Rubin SC; Kaiser LR; June CH
Cancer Res; 2001 Jun; 61(12):4766-72. PubMed ID: 11406550
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
[TBL] [Abstract][Full Text] [Related]
20. Human fibroblasts transduced with CD80 or CD86 efficiently trans-costimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and autoimmunity.
Smythe JA; Fink PD; Logan GJ; Lees J; Rowe PB; Alexander IE
J Immunol; 1999 Sep; 163(6):3239-49. PubMed ID: 10477593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]